As Sanofi prepares to halt U.S. marketing of its dengue vaccine in 2026, locally acquired infections in the country are ...

CD&R this week entered exclusive talks with drugmaker Sanofi to buy half of its consumer arm, Opella. Getting burned on ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) will present data from the Phase 3 LIBERTY-CUPID Study C evaluating the investigational use ...

Data from the phase 3 LIBERTY-CUPID Study C evaluating the investigational use of Dupixent in biologic-naive patients with uncontrolled chronic ...

Agomab Therapeutics NV (‘Agomab’) today announced a $89 million (€82.1 million) Series D financing round, with participation from new investors Sanofi and Invus, as well as existing investors.

Agomab Therapeutics is benefiting from Sanofi’s push to become an immunology powerhouse. The Antwerp-based biotech said ...

US private equity firm Clayton Dubilier & Rice thought it had a deal to buy Sanofi’s consumer business. Losing bidder PAI ...

Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI Dupixent significantly reduced itch and hive activity from baseline; 41% of patients ...

The insulin is facing supply shortages as diabetes patients increasingly turn to GLP-1 weight loss drugs such as Ozempic and ...

The French government has warned the United States investment company buying the consumer healthcare division of drugmaker Sanofi that it will incur penalties of more than 100 million euros ($107.6 ...

Olympic gold medalist gymnast Shawn Johnson East had respiratory syncytial virus-related experiences with all 3 of her ...

The global ulcerated necrobiosis lipoidica management market is poised for significant growth, with an anticipated valuation ...